Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.
Year: 2015
Type: article
Abstract: Diabetes is on the rise at an alarming rate in the United States. An estimated 9.3% of the US population, or 29.1 million people, are affected by diabetes.1 Furthermore, approximately 37% of all US adults (51% of people aged ≥65 years) have prediabetes, a condition that greatly increases their risk for developing diabetes.1 The prevalence of diabetes is projected to increase from 1 in 10 adults today to 1 in 3 adults by 2050, based on current trends and the aging of the population over the next few decades.2 Type 2 diabetes mellitus, a type of diabetes characterized by insulin resistance and the gradual decline in the ability of the pancreas to produce insulin, accounts for an estimated 90% to 95% of all cases of diabetes.1
Associated with serious comorbidities, diabetes is the seventh leading cause of mortality and a major cause of stroke, heart disease, kidney failure, blindness, and other conditions.1 Moreover, diabetes is associated with microvascular, macrovascular, and neuropathic complications that impact health and quality of life.1
The annual healthcare costs attributable to diabetes in the United States totaled $245 billion in 2012, including $176 billion in direct medical costs and $69 billion in indirect costs (ie, absenteeism, reduced or lost productivity, and disability).3 Overall, the medical costs for people with diabetes are more than twice as high as costs for people without diabetes, and more than 1 in 5 US healthcare dollars is spent on diabetes care.3
Diabetes management is complex, requiring multiple considerations beyond glycemic control.4 Approaches include incorporating lifestyle changes and self-management, providing appropriate education, minimizing the risk of weight gain, minimizing the risk of hypoglycemia, and targeting the patient's hemoglobin (Hb) A1c goal on an individual basis, which is based on factors such as age, comorbid conditions, disease duration, adherence, and others.5 Patients must be monitored on an ongoing basis, and the effectiveness of their therapies must be evaluated until stable results are achieved.5
Improvements in glycemic control are associated with improved outcomes for patients with type 2 diabetes. Lowering the HbA1c level to ≤7% in appropriate patients is associated with a reduction in diabetes-related microvascular complications (ie, diabetic neuropathy, nephropathy, and retinopathy).6 Pharmacologic treatments include metformin, sulfonylureas, meglitinides, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, insulin, and sodium glucose cotransporter-2 (SGLT2) inhibitors—the most recent class of antidiabetic agents.7
Source: PubMed
Author: Loretta Fala
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: empagliflozin, SGLT2 inhibitors, type 2 diabetes, FDA approval, glycemic control, HbA1c, diabetic nephropathy, cardiovascular outcomes, heart failure, drug safety, adverse events, drug interactions, cost-effectiveness, diabetes management, prediabetes, health care costs, diabetes complications, lifestyle modification, self-management
Open Access status: green
OpenAlex ID: W2183777414
